» Articles » PMID: 23967807

Clinical Profile, Morbidity, and Outcome of Adult-onset Generalized Pustular Psoriasis: Analysis of 102 Cases Seen in a Tertiary Hospital in Johor, Malaysia

Overview
Journal Int J Dermatol
Specialty Dermatology
Date 2013 Aug 24
PMID 23967807
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Generalized pustular psoriasis (GPP) is a severe but rare variant of psoriasis. Our objective is to review the clinical profile, comorbidities, and outcome of patients with GPP.

Materials And Methods: A retrospective note review of all patients with adult-onset GPP.

Results: A total of 102 patients with adult-onset GPP were diagnosed between 1989 and November 2011, with a female to male ratio of 2 : 1. The mean age at onset of GPP was 40.9 years (range: 21-81 years). Acute GPP was the most common variant seen (95 cases), followed by four localized variants of GPP and three with annular pustular psoriasis. Fever and painful skin were present in 89% of patients, arthritis in 34.7%, and leukocytosis in 78.4%. Common triggers were systemic steroids (45 cases), pregnancy (17 cases), and upper respiratory tract infections (16 cases). A positive family history of psoriasis and GPP was present in 29% and 11%, respectively. Comorbidities included obesity (42.9%), hypertension (25.7%), hyperlipidemia (25.7%), and diabetes mellitus (23.7%). The mean duration of admission and pustular flare for acute GPP was 10.3 days (range: 3-44 days) and 16 days (range: 7-60 days), respectively. Fifty-four patients responded to systemic retinoid, 21 to methotrexate, eight to cyclosporine, and one to adalimumab, but recurrences were common.

Conclusions: Our study confirms the poor response of GPP to currently available anti-psoriatic agents, with frequent flare-ups. There is a need for a more effective targeted therapy for this condition.

Citing Articles

Management of Chronic Generalized Pustular Psoriasis: A Review and Expert Opinion.

Elewski B, Lebwohl M J Psoriasis Psoriatic Arthritis. 2025; :24755303251318976.

PMID: 39906749 PMC: 11789050. DOI: 10.1177/24755303251318976.


Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis.

Chen B, Liu Q, Dong X, Bai Y Front Immunol. 2024; 15:1462158.

PMID: 39469713 PMC: 11513292. DOI: 10.3389/fimmu.2024.1462158.


Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis.

Choon S, Foley P, Asawanonda P, Fujita H, Jo S, Shi Y J Dermatol. 2024; 51(12):1579-1595.

PMID: 39390737 PMC: 11624156. DOI: 10.1111/1346-8138.17471.


The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas' Psoriasis Registry.

Lebwohl M, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M J Psoriasis Psoriatic Arthritis. 2024; 7(2):71-78.

PMID: 39296823 PMC: 11361522. DOI: 10.1177/24755303221079814.


Management of Pustular Psoriasis; The Way Ahead.

Parasramani S, Kar B, Tahiliani S, Parthasarathi A, Neema S, Ganguly S Indian J Dermatol. 2024; 69(3):241-248.

PMID: 39119327 PMC: 11305487. DOI: 10.4103/ijd.ijd_165_24.